Jean‐Marc Tourani

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

J. Guigay, Anne Aupérin, Jérôme Fayette et al. · The Lancet Oncology · 2021 · 214 citations

Gortec 2014-01 Tpextreme, Neoadjuvant Therapy, Medicine +11

Multicenter Study of a Frozen Glove to Prevent Docetaxel-Induced Onycholysis and Cutaneous Toxicity of the Hand

Florian Scotté, Jean‐Marc Tourani, Eugéniu Banu et al. · Journal of Clinical Oncology · 2005 · 193 citations

Cell-mediated autoimmunity in paraneoplastic neurological syndromes with anti-Hu antibodies

B Benyahia, Roland Liblau, Jean‐Marc Tourani et al. · Annals of Neurology · 1999 · 156 citations · Full text

Induction Chemotherapy Followed by Cetuximab Radiotherapy Is Not Superior to Concurrent Chemoradiotherapy for Head and Neck Carcinomas: Results of the GORTEC 2007-02 Phase III Randomized Trial

Lionnel Geoffrois, Laurent Martin, D. De Raucourt et al. · Journal of Clinical Oncology · 2018 · 143 citations

STAT3 is essential for the maintenance of neurosphere‐initiating tumor cells in patients with glioblastomas: A potential for targeted therapy?

Claire Villalva, Severine Martin‐Lannerée, Ulrich Cortes et al. · International Journal of Cancer · 2010 · 103 citations · Full text

Tumor Cells, Transcription Stat3, Cancer Biology +16